Substance + claimed effects

Microdosing is the repeated ingestion of a sub-perceptual dose of a classic psychedelic — typically 10–20 μg of LSD or 0.1–0.3 g of dried psilocybin mushrooms (roughly 1/10–1/20 of a recreational dose) — on an intermittent schedule, most commonly one day on, two days off (the Fadiman protocol) over a 4–8 week course Fadiman 2011. The claimed effect profile across the popular literature and observational surveys covers mood, focus and creativity, anxiety reduction, and secondary claims around ADHD symptom relief, mild depression, social connection, and energy Anderson et al. 2019Hutten et al. 2019. The signature claim — and the one this entry has to adjudicate — is that the practice delivers these effects without any acute psychedelic experience. Scope of this entry: psilocybin and LSD microdosing in adults, intermittent-schedule (Fadiman, Stamets, similar). Out of scope: full-dose psychedelic-assisted therapy, MDMA microdosing, ketamine microdosing, herbal "stacks" sold as microdose products that contain no psilocybin.

Evidence by addressing question

Mechanism

Classic psychedelics agonise the 5-HT_2A receptor, which in full doses produces the hallucinogenic state and in animal models drives a transient surge of dendritic spine growth and synaptogenesis in cortical pyramidal neurons — the "psychoplastogen" hypothesis Cameron et al. 2018Calder & Hasler 2023. The microdose proposition extrapolates: if a sub-perceptual dose still occupies enough 5-HT_2A receptors to nudge plasticity without producing the trip, accumulated low-dose exposure should remodel mood and cognitive circuits the way a course of an SSRI would, but faster.

Two pieces of human pharmacology partially support this. Hutten and colleagues found that a single 20 μg LSD dose in healthy volunteers raised plasma BDNF starting ~4 hours after dosing in a dose-proportional way Hutten et al. 2020. de Wit's controlled lab studies confirm 13–26 μg LSD reliably produces small subjective effects (vigor, "bliss", some anxiety) and is psychoactive in measurable but non-hallucinogenic ways de Wit et al. 2022. The pharmacology floor exists. The question is whether occupancy at the sub-perceptual range, repeated weekly, accumulates into anything clinically meaningful.

A meta-analysis of psychoplastogen effects on peripheral BDNF in humans found mixed results — single full-dose psychedelic sessions do not reliably move plasma BDNF, and the chronic-microdose data are too thin to pool. The neuroplasticity story is more secure at the receptor / animal / dendrite level than at the human-biomarker level Calder & Hasler 2023.

Evidence (does it actually work)

This is the section where the field genuinely disagrees. Two literatures, in dialogue:

Open-label, observational, and survey data: broadly positive. Anderson et al. coded qualitative reports from 278 microdosers and found self-reported benefits in mood (~27%) and focus (~15%), alongside physiological discomfort (~18%) and anxiety (~7%) Anderson et al. 2019. Hutten et al. surveyed ~1,116 microdosers and confirmed similar motive and side-effect distributions Hutten et al. 2019. Polito and Stevenson tracked 98 microdosers over 6 weeks with daily ratings; pre/post showed reduced depression and stress and lower distractibility, but also increased neuroticism Polito & Stevenson 2019. Prochazkova and colleagues, at a Dutch Psychedelic Society event, found improved divergent and convergent thinking after psilocybin truffles — but the design was open-label, no blinding Prochazkova et al. 2018.

Placebo-controlled data: largely null. Szigeti et al. ran the largest microdosing study to date — 191 self-blinded citizen-scientists, randomised between microdose capsules and placebo. All psychological outcomes (well-being, depression, anxiety, social connectedness) improved over 4 weeks. Both arms. The microdose vs. placebo between-group difference was not significant; small acute differences disappeared once participants who correctly guessed their arm were accounted for Szigeti et al. 2021. de Wit's lab gave 56 healthy adults four repeated sessions of placebo, 13 μg, or 26 μg LSD in double-blind conditions. No meaningful effect on mood, working memory, or cognitive performance; creativity tasks actually slowed; tolerance built across sessions de Wit et al. 2022. Cavanna et al., a double-blind crossover of psilocybin mushrooms, found no significant cognitive or mood improvement beyond placebo Cavanna et al. 2022. Marschall et al. (preregistered, field + lab) found no effect of psilocybin microdosing on emotion-related symptoms or processing Marschall et al. 2022.

The 2024 synthesis. Polito and Liknaitzky's rapid review of every controlled low-dose LSD and psilocybin study concluded that, while some acute physiological and subjective signals are real (mild stimulant-like effects, BDNF nudges, EEG changes), the headline claims — improved mood, focus, creativity, anxiety — have not separated from placebo in blinded designs. The case for "microdosing as a productivity hack" is, at best, unconfirmed and, at worst, a clean placebo effect amplified by demand characteristics and confirmation bias on dose days Polito & Liknaitzky 2024.

Where a real signal might survive. Two pockets. First, depressed patients: a 2024 de Wit lab follow-up found that 13 μg LSD produced larger subjective mood effects in volunteers with elevated baseline depression scores than in euthymic controls, with a measurable decrement on the Beck Depression Inventory 48 hours after dosing Molla et al. 2024. Second, ADHD: a 4-week naturalistic study of adults with ADHD reported symptom relief that participants rated as more effective than their conventional treatments — but the design was not placebo-controlled and the effect-size estimate is fragile Haijen et al. 2024. Several phase-2 trials in MDD and ADHD are ongoing.

Protocol

The dominant schedule is the Fadiman protocol: 10–20 μg LSD or 0.1–0.3 g dried psilocybin, one day on, two days off, in a 6-week cycle followed by 2–4 weeks abstinent Fadiman 2011. The two-day washout is rationalised as preventing 5-HT_2A tolerance (which Buchborn and others have shown develops rapidly with daily dosing) and as preserving a perceptible contrast between dose and non-dose days. The Stamets stack — 4 days on, 3 days off, with lion's mane (Hericium erinaceus) and niacin — is the second-most-common variant; the lion's mane / niacin addition has no controlled evidence behind it. Survey data: ~33% of microdosers use 1-on/2-off; ~20% use 1-on/3-off; the rest use various adaptations Hutten et al. 2019.

Dose calibration is the practical problem. Psilocybin content in dried Psilocybe cubensis mushrooms ranges roughly 0.5–1.5% by weight and varies sharply by strain, growing conditions, and storage time. 0.1 g of a high-potency batch can be perceptible; 0.3 g of a weak batch may be inert. LSD blotter is more consistent (paper assumed 100 μg/tab; quartering yields nominal 25 μg) but blotter content also varies substantially batch to batch, and dilution into a volumetric tincture is the only way to deliver a predictable dose. The Szigeti study, notably, found that participants in placebo and microdose arms reported similar acute "drug effects," reinforcing that perceived intensity is a poor guide to actual occupancy Szigeti et al. 2021.

Contraindications

Cardiac. Classic psychedelics bind the 5-HT_2B receptor with high affinity — psilocin's Ki at 5-HT_2B is ~3.6 nM, comparable to or stronger than 5-HT_2A — and chronic 5-HT_2B agonism is the mechanism by which fenfluramine and pergolide caused valvular heart disease and were withdrawn from market Tagen et al. 2023. The theoretical concern: a Fadiman-protocol microdoser exposes the heart to repeated 5-HT_2B agonism for months or years, in a pattern that — by receptor pharmacology alone — resembles the drug regimens that caused VHD historically. Rouaud and colleagues' comparative analysis frames the chronic microdose exposure as the part of the schedule that most warrants caution, since acute occupancy at a single full dose is short and intermittent Rouaud et al. 2024. A 2025 mouse study found no echocardiographic changes after 4–8 weeks of subhallucinogenic LSD in mice — partial reassurance, but mouse hearts and human hearts respond differently to 5-HT_2B ligands, and the exposure window is short relative to the multi-year microdose courses some users report. The honest read: no human cardiac harm has been demonstrated, but the pharmacological case for caution is real, especially for users with existing valvulopathy or pulmonary hypertension.

Psychiatric. Personal or family history of psychotic disorders (schizophrenia, schizoaffective, bipolar I) is a standard exclusion from clinical psychedelic trials; the case for microdoses being categorically safer is mechanistic plausibility, not evidence. Polito and Stevenson observed increased neuroticism after 6 weeks of microdosing — a direction-of-effect signal that does not point at "uniformly calming" Polito & Stevenson 2019.

Drug interactions. Combining serotonergic psychedelics with SSRIs, SNRIs, MAOIs, lithium, or tramadol is not benign — case reports of serotonin syndrome and seizures with lithium combinations exist. Pregnancy and breastfeeding: no controlled human data; standard precautionary exclusion.

Anxiety on dose days. Hutten's survey put physiological side effects (headache, fatigue, nausea, sleep disruption) and acute anxiety at ~6% of microdosers Hutten et al. 2019. de Wit's lab trial saw 6/40 LSD participants need a titration protocol for jitteriness vs. 1/40 placebo de Wit et al. 2022.

Misconceptions

Three to flag. First: "Microdosing is sub-perceptual, therefore consequence-free." Sub-perceptual to the user is not the same as inactive at receptors; 5-HT_2A and 5-HT_2B occupancy is non-zero at standard microdoses, BDNF is dose-proportionally elevated, and EEG shifts are measurable Hutten et al. 2020. The "safe because invisible" inference is wrong on its face. Second: "Open-label microdosers' lived experience is the evidence." It is evidence of a population that overwhelmingly believes the practice will help them, doses on a schedule that creates a daily expectancy ritual, and self-reports on dose days vs. non-dose days. That is a near-perfect placebo-generation machine; Szigeti's self-blinded comparison is what the open-label data fail to deliver Szigeti et al. 2021. Third: "Lion's mane and niacin in the Stamets stack do something." No controlled evidence behind the combination; the niacin "flush" is a body-cue, not a pharmacological synergy.

Stakes / Payoff

The honest forecast under current evidence: a typical healthy adult who follows a Fadiman protocol for 6 weeks will likely feel mildly better, attribute it to the microdose, and be partially or wholly experiencing a placebo. They are unlikely to be harmed acutely; they may experience headaches, anxiety, or sleep disruption a small fraction of dose days; the multi-year cardiac concern is theoretical but real. The opportunity cost is meaningful — the time, money, and legal exposure invested could have funded behaviours with better-confirmed mood and focus payoffs (sleep, exercise, light exposure, real psychotherapy). For a depressed adult, the picture is less settled: signal exists, blinded trials are ongoing, conventional treatments remain the default.

Practicalities

Legal status, addressed in §3b "audience"-equivalent below. Supply: outside Colorado and Oregon's licensed channels, all sourcing is unregulated and illegal under federal law, which means product is unverified for purity, potency, and adulteration. Cost ranges widely; home cultivation of psilocybin mushrooms in Colorado is decriminalized for personal use, which is the only clearly low-cost legal supply chain in the US. Dose-titrating LSD in a volumetric tincture and capsuling dried mushroom powder are the standard hobbyist approaches; both require equipment and discipline most people don't have.

Audience (legal status)

Federal: psilocybin and LSD are Schedule I under the Controlled Substances Act; possession is a federal crime regardless of dose, with no medical exception DEA 2024. Psilocybin holds FDA "breakthrough therapy" designation for treatment-resistant depression (2018) and major depressive disorder (2019), but the FDA designation accelerates trial path, not rescheduling. State-level (as of mid-2026):

• Colorado: Proposition 122 (2022) decriminalized personal possession, gifting, and home cultivation of psilocybin mushrooms for adults 21+. Licensed "healing centers" launched in 2025. The most protective state for personal-use microdosing Colorado Prop 122 2022.
• Oregon: Measure 109 (2020) created a licensed psilocybin services program for adults 21+ (operating since 2023, ~370 facilitators by mid-2025). Sessions are full-dose, facilitator-supervised, $1,200–$3,500. Measure 110's drug decriminalization was partially rolled back by HB 4002 (2024); personal possession outside service centers is again a misdemeanor.
• New Mexico: Medical Psilocybin Act signed April 2025; medical-access framework in build-out.
• ~30 cities (Oakland, San Francisco, Seattle, Detroit, Ann Arbor, Somerville, others) have passed local deprioritization resolutions. These do not change state or federal law.

For the at-home microdoser, the practical legal picture: only Colorado offers a clear personal-use safe harbour. Oregon's service-center model is structurally not a microdosing channel. Everywhere else, microdosing is a federal felony and a state crime, with enforcement priority varying by jurisdiction.

Alternatives

For mood and well-being: SSRI / SNRI trial with a clinician (slow, evidence-rich), CBT or behavioural activation (slow, evidence-rich), exercise (evidence-rich), full-dose psilocybin-assisted therapy in jurisdictions where it is licensed (Oregon, Colorado healing centers). For focus / cognitive performance: sleep optimisation, caffeine, methylphenidate / amphetamine with a clinician for diagnosed ADHD. The honest framing: the conditions microdosing claims to treat (mild depression, mild anxiety, attention problems, blocked creativity) all have interventions with better evidence and clearer legal status.

Failure modes

Three patterns that show up in the qualitative literature. Dose creep: the user gradually increases dose chasing a fading effect, eventually crossing into perceptual territory at work or in public — the "tolerance" Fadiman's two-day washout is supposed to prevent, but does only imperfectly. Expectancy collapse: the user notices the placebo arm of Szigeti's study did roughly as well, the ritual stops feeling magical, and the practice is dropped — often without honest reflection on whether the original benefit was ever pharmacological. Stack confusion: users buying "microdose products" (capsules sold online) often receive material containing no psilocybin or unknown adulterants, attribute effects to a substance they didn't actually take, and either get nothing or get an unpredictable mix of caffeine, theobromine, kratom, or research chemicals.

Out-of-scope

Full-dose psilocybin-assisted therapy for treatment-resistant depression is a separate, much better-evidenced entry (multiple positive phase-2 / phase-3 RCTs). Ketamine and MDMA microdosing are not covered here. Long-term cardiovascular surveillance for psychedelic users is an open clinical question; cohorts don't exist yet.

The credibility range

Optimist case

Psychedelics produce real, dose-proportional changes in cerebral pharmacology even at the microdose floor: 5-HT_2A occupancy, BDNF elevation, EEG signature shifts, subjective mood lift Hutten et al. 2020de Wit et al. 2022. The "psychoplastogen" framework — a transient open window of cortical plasticity, repeated weekly — has a strong preclinical mechanistic basis Cameron et al. 2018Calder & Hasler 2023. The phenomenology reported by tens of thousands of microdosers — better mood, more focus, more energy, less anxiety — is improbably consistent across cultures and personality types Anderson et al. 2019Hutten et al. 2019. Depressed adults appear to respond more than euthymic controls, hinting that the populations recruited into blinded trials (healthy young volunteers with limited room to move on mood scales) may have masked a real subgroup-level effect Molla et al. 2024. The blinded null findings are limited by sample size, short duration, and demand to recruit experienced users who can be unblinded by acute cues — the methodological bar for a microdose effect is harder to clear than for full doses, but the absence of evidence is not evidence of absence. The Haijen ADHD signal is consistent with this Haijen et al. 2024.

Skeptic case

The headline claims — mood, focus, creativity — have been tested in multiple double-blind designs and consistently failed to separate from placebo Szigeti et al. 2021de Wit et al. 2022Cavanna et al. 2022Marschall et al. 2022. Szigeti's self-blinded study is methodologically the closest to "real-world microdosing" of any controlled study, and the placebo arm matched the microdose arm on every psychological outcome that matters. The open-label literature emerges from a population that paid money, sought a substance, calibrated a dose, scheduled a ritual, and tracked self-report measures designed to detect subtle subjective shifts — the maximum-placebo configuration. The increase in neuroticism in Polito and Stevenson's prospective tracking is a counter-direction-of-effect finding that the optimist case has not absorbed Polito & Stevenson 2019. The 5-HT_2B cardiac concern is unresolved and the fenfluramine analogue is uncomfortably tight Tagen et al. 2023Rouaud et al. 2024. The legal exposure is real. The 2024 rapid review concluded the practice is, on current evidence, best understood as a placebo-mediated ritual Polito & Liknaitzky 2024.

Author's call

Lean skeptic, but not dismissive. The phenomenon is real in the sense that something pharmacological is happening at the microdose floor (BDNF, EEG, subjective drug effect); the headline mood and focus claims, after four blinded trials, are most parsimoniously explained as placebo amplified by ritual and expectancy. The most defensible operating model: microdosing is a low-evidence, high-controversy practice with a real placebo component, a plausible (but unconfirmed) subgroup signal in mild-to-moderate depression, an unresolved long-term cardiac safety question, and a legal status that makes it a federal felony almost everywhere in the United States. meta.evidence = 2: sparse and mixed; mechanism plausible but trials thin or null. meta.controversy = 4: foundational disagreement between two literatures (open-label community vs. blinded controlled), with neither side having moved the other since 2021.

Stakeholder + incentive map

• Microdosing institutes, retreat brands, "stack" sellers (Microdosing Institute, Field Trip, online vendors) — commercial incentive to push the practice as evidence-supported. Margins on online microdose products are high; the legal grey makes accountability for content low.
• Public intellectuals and authors — Fadiman, Stamets, Pollan — have shaped the protocol vocabulary and the cultural narrative. Their incentive is the narrative, not the trial data.
• Bay Area / tech-worker subculture — visible early-adopter community that reinforced the productivity-hack framing in popular media.
• Biotech (Compass Pathways, MindMed, atai, Cybin) — focused on full-dose psychedelic-assisted therapy as the regulatory path, not microdosing. Some have run microdose trials (MindMed's MDLSD); the commercial bet is on macrodoses with insurance reimbursement, not sub-perceptual courses.
• Academic researchers — Polito, Szigeti, Erritzoe, de Wit, Carhart-Harris, Kuypers, van Elk — have run the blinded trials that now define the skeptical pole. Academic incentive favours publishing null findings if they overturn a popular claim.
• Regulators — DEA holds the federal Schedule I; FDA grants breakthrough designation for full-dose psilocybin therapy; state legislatures vary widely. Counter-incentive: psychedelic legalization is a politically charged file with bipartisan splits.
• Conventional psychiatry — has limited direct exposure to microdosing in patient populations; some clinicians ask, most do not screen. Counter-incentive: workflows are built around SSRI / CBT / referral, not novel-substance management.

Population variability

• Depressed adults may respond more than euthymic controls — Molla et al. 2024 showed larger subjective and BDI-2 effects of 13 μg LSD in elevated-baseline-depression participants 48h post-dose Molla et al. 2024.
• Adults with ADHD — Haijen et al. 2024 naturalistic data suggest symptom relief that participants rate above conventional treatment, but unblinded Haijen et al. 2024.
• Healthy, euthymic young adults (the population most blinded trials recruit) — most likely to show null placebo-controlled effects; ceiling on mood / cognitive measures.
• Females and older microdosers are over-represented in exclusive-microdose subgroups (vs. mixed micro/macro users), per the 2024 demographic analysis. The 2025 RAND survey put US past-year microdosing at ~10M adults, with psilocybin dominant RAND 2026.
• People on serotonergic medications — SSRIs may blunt subjective response (5-HT_2A downregulation); MAOIs, lithium, and tramadol carry real interaction risk.
• Anyone with structural heart disease or valvulopathy — theoretical 5-HT_2B concern is concentrated here Tagen et al. 2023.
• Family history of psychosis or bipolar I — standard exclusion in clinical trials; no controlled microdose data justifies a different default.

Knowledge gaps

The decisive blinded trials in the populations most likely to benefit — adults with mild-to-moderate depression, adults with ADHD — are ongoing as of 2026 and have not produced results that move the placebo-vs-real-effect question. The phase-2 psilocybin-microdose-for-MDD protocol (PMC12926881) is the trial to watch. Long-term cardiac safety data in chronic microdosers do not exist; the existing 5-HT_2B concern is grounded in receptor pharmacology and fenfluramine analogy, not human echocardiographic data over multi-year exposures. Whether the Stamets-style stack (psilocybin + lion's mane + niacin) does anything separable from psilocybin alone has never been controlled-trial tested. Dose-content variability in real-world sourcing (home-grown mushrooms, blotter LSD) means that nominal microdose protocols deliver actual doses that vary by ~5–10× — a confound the placebo-controlled trials minimise by lab-titrating doses, but that the field rarely controls in real-world use.

Brief vs. article coverage. The brief named mood, focus, creativity, anxiety, placebo-controlled outcomes, and legal status. All six covered. Mood, focus, creativity, and anxiety are aggregated under the evidence section rather than given separate addressing sections, because the blinded-trial finding for all four is "no separation from placebo" and four separate sections would have re-litigated the same point. Placebo-controlled outcomes are the spine of the evidence section. Legal status got its own audience-keyed section because the criminal-exposure angle is load-bearing for a US reader's decide-or-not call.

Scoring difficulty: mood. Scored at 2, not 1, despite four blinded null trials. Two reasons. First, on-dose subjective lift is real and consistent across both arms in self-blinded designs — the felt experience exists even if it's placebo-mediated. Second, the Molla 2024 depression-subgroup signal is the one piece of blinded evidence pointing at a real drug effect, and the meta should reflect the substance's effect on the population that might benefit, not just on the healthy-volunteer cohort that doesn't. A reviewer who thinks mood = 1 has a defensible case; the call here leans on the depression subgroup.

Scoring difficulty: evidence. Sat between 1 and 2 for the same reason. Lands at 2 because mechanism is real (BDNF, 5-HT_2A occupancy, EEG shifts), and the depression subgroup signal exists. A strict reading of the blinded headline-claim literature would push toward 1; that would understate the mechanism floor.

Controversy at 4, not 3. "Active debate among reasonable experts" understates the gap. The blinded-trial researchers (Szigeti, Polito, de Wit, Cavanna, Marschall, van Elk) and the community / observational researchers (Anderson, Hutten, Fadiman) have been talking past each other since 2018 with no convergence. That reads as foundational disagreement, hence 4.

Action decide, cadence course. Considered know + as-needed. decide won because the reader is genuinely being handed a tradeoff (legal risk, theoretical cardiac risk, placebo-likely benefit, depression subgroup possibility). course won over weekly because the Fadiman protocol is structurally a time-bounded 6-week cycle, not an ongoing habit.

Contraindications. Picked pregnancy, breastfeeding, cardiac-condition, uncontrolled-hypertension from the closed vocabulary. Schizophrenia / bipolar / family-history-of-psychosis exclusions are real and surfaced in the contraindications prose, but the closed vocabulary doesn't include a psychiatric token, so they live in the warning callout rather than the structured field. Worth flagging for a future schema expansion: a psychotic-disorder-history contraindication token would carry real weight across multiple entries.

Excluded / out-of-scope.

• Full-dose psilocybin-assisted therapy — separate entry, much better-evidenced. Linked in out-of-scope / alternatives; should be created as psilocybin-assisted-therapy.
• MDMA microdosing, ketamine microdosing — separate substances, separate evidence bases, separate legal frameworks. Out of this entry's substance scope.
• "Microdose stack" supplement products (the online capsule market) — touched briefly under failure-modes because the adulteration problem is load-bearing for the reader. Not given a separate section.
• Buchborn 5-HT_2A tolerance kinetics — informed the protocol section's rationale for the 2-day washout but not cited inline (tertiary evidence, not load-bearing).

Future-link candidates (entries that don't yet exist): psilocybin-assisted-therapy, full-dose-psychedelic-therapy-for-depression, possibly a stand-alone 5-ht2b-cardiovascular-risk entry if the cardiac literature firms up.

Hard call on tone. Wrote the article skeptical-but-not-dismissive, which is where the credibility-range author's-call landed. An earlier draft was more uniformly negative; the revision restored room for the depression subgroup signal and for the mechanism floor, on the principle that under-rating a possible real effect is as bad an error as over-rating a placebo. A reviewer who wants the article to land harder on the placebo case (or softer on it) would be making a defensible different call.